Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Conditions

• Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
• Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma
• Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma
• Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma
• Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma
• Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma

Interventions

• BIOLOGICAL: Anti-VEGF Monoclonal Antibody
• BIOLOGICAL: Bevacizumab
• PROCEDURE: Biospecimen Collection
• DRUG: Carboplatin
• PROCEDURE: Computed Tomography
• PROCEDURE: Echocardiography Test
• DRUG: Gemcitabine
• PROCEDURE: Magnetic Resonance Imaging
• DRUG: Pegylated Liposomal Doxorubicin Hydrochloride
• BIOLOGICAL: Sacituzumab Govitecan

Sponsor

National Cancer Institute (NCI)